This is the best story I've seen on the recent Whitehouse Station announcement of the appointment of a pharma outsider (Vietnamese by background) as its global head of strategy. A few days after his appointment, he announced his resignation from WuXi PharmaTech’s board, though -- just to be clear. Mr. Do, 45, is an international M&A maven, and a veteran of TE Connectivity and Lenovo -- both global electronics firms:
. . . .Merck, known as MSD outside the United States and Canada, selected a member of WuXi PharmaTech’s board as its own Chief Strategy Director (see story). Cuong Viet Do has experience in both healthcare and M&A, in addition to familiarity with China business. From 1989 to 2006, Do was a director and senior partner at McKinsey & Company, where he worked in global healthcare and then high-tech/corporate finance in China and Asia. Because of his extensive experience in Asia, Do’s appointment underscores the significance of China and Asia to Merck. . . .
Tomorrow we may have a verdict in the Secrest (fifth bellwether) Fosamax® ONJ trial. So, do stay tuned.